Globus Medical (NYSE:GMED) Releases FY 2025 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 3.400-3.500 for the period, compared to the consensus EPS estimate of 3.420. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion. Globus Medical also updated its FY 2024 guidance to EPS.

Globus Medical Price Performance

Shares of Globus Medical stock opened at $86.34 on Thursday. The stock has a market capitalization of $11.76 billion, a price-to-earnings ratio of 128.87, a price-to-earnings-growth ratio of 1.97 and a beta of 1.19. The business has a 50-day moving average of $82.56 and a 200 day moving average of $74.94. Globus Medical has a 12 month low of $49.33 and a 12 month high of $87.22.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.65 by $0.18. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The business had revenue of $625.71 million during the quarter, compared to analyst estimates of $604.69 million. During the same quarter last year, the firm posted $0.57 earnings per share. The business’s revenue for the quarter was up 63.1% compared to the same quarter last year. Equities research analysts anticipate that Globus Medical will post 2.97 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on GMED shares. Royal Bank of Canada increased their price objective on Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th. Bank of America increased their price target on Globus Medical from $55.00 to $80.00 and gave the company an “underperform” rating in a research report on Wednesday, November 6th. Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a research report on Wednesday, November 6th. Canaccord Genuity Group upped their target price on shares of Globus Medical from $85.00 to $92.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, Morgan Stanley upgraded shares of Globus Medical from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $83.00 to $100.00 in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and an average price target of $94.55.

Insider Activity

In other Globus Medical news, Director David D. Davidar sold 30,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the transaction, the director now owns 536,275 shares of the company’s stock, valued at $40,242,076. The trade was a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Daniel T. Scavilla sold 60,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total value of $4,801,200.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 97,500 shares of company stock worth $7,674,950. Corporate insiders own 18.54% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.